Hebing Zhou

Dr. Hebing Zhou


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YZYue Zhang
Yue Zhang
XCXiao-Lei Chen
Xiao-Lei Chen
Wenming ChenWenming Chen
Wenming Chen
HZHebing Zhou
Hebing Zhou
To establish a nomogram for predicting the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM), 304 patients with newly diagnosed MM were recruited between June 1, 2010, and June 30, 2015, from the Beijing Chaoyang Hospital, Capital Medical University, and randomly divided into training (n=214) and validation (n=90) cohorts. The Kaplan-Meier method and the Cox proportional hazards regression model were used to evaluate the prognostic effects of multiple clinical and laboratory parameters on survival. Significant prognostic factors were combined to build a nomogram. The discriminative ability and predictive accuracy of the nomogram were evaluated using the index of concordance (C-index) and calibration curves and compared with the five staging systems currently used for MM. Multivariate analysis of the training cohort revealed that the age at diagnosis, clonal bone marrow plasma cells, serum lactate dehydrogenase, serumβ2-microglobulin, and del (17p) were independent risk factors for OS and were used to establish the nomogram. The C-index value of the nomogram for predicting OS was 0.749, which was significantly higher than the C-indices of the five most common staging systems currently used for MM. In the validation cohort, the C-index for nomogram-based predictions was 0.711 for OS, and the nomogram discrimination was better than the above mentioned five staging systems (P<0.001). All calibration curves revealed good consistency between predicted and actual survivals. The proposed nomogram is more accurate in predicting the prognoses of patients with newly diagnosed MM.

18 June 2020 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
TCTingting Chen
Tingting Chen
JZJuan Zhang
Juan Zhang
HZHui Zeng
Hui Zeng
YZYue Zhang
Yue Zhang
YZYong Zhang
Yong Zhang
HZHebing Zhou
Hebing Zhou
The antitumor enzyme L‑asparaginase (L‑Asp) has commonly been used for the treatment of acute lymphoblastic leukemia. However, the effects of L‑Asp on acute myeloid leukemia (AML) and their underlying mechanisms have not been fully elucidated. In the present study, the effects of L‑Asp on cell proliferation and apoptosis were investigated using the AML cell lines U937, HL‑60 and KG‑1a. The effects of combining L‑Asp with mitoxantrone (MIT) and cytarabine (Ara‑c) were also analyzed. The combination of MIT and Ara‑C is known as MA therapy, and is a widely used therapeutic regimen for the treatment of elderly patients with refractory AML. When applied alone, L‑Asp inhibited cell proliferation and induced apoptosis in each of the cell lines tested. Furthermore, the combined use of L‑Asp with MA therapy further potentiated the inhibition of cell proliferation while increasing the induction of apoptosis. These findings provide evidence for the potential antitumor effect of L‑Asp in AML, and indicate that improved efficacy maybe achieved by combining L‑Asp with MIT and Ara‑c. This combination may provide a promising new therapeutic strategy for the treatment of AML.

9 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YZYue Zhang
Yue Zhang
JZJuan Zhang
Juan Zhang
HZHui Zeng
Hui Zeng
XZXiao-Huan Zhou
Xiao-Huan Zhou
HZHebing Zhou
Hebing Zhou
Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study

13 June 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
TCtingting chen
tingting chen
JZJuan Zhang
Juan Zhang
HZHui Zeng
Hui Zeng
YZYue Zhang
Yue Zhang
YZYong Zhang
Yong Zhang
HZHebing Zhou
Hebing Zhou
Environmental and health issues have become a major focus of research worldwide in recent years. Particulate matter with diameter ≤2.5 µm (PM2.5) is a common air pollutant that has been demonstrated to be associated with various diseases, including acute myeloid leukemia (AML). In the present study, the effects of PM2.5 on the proliferation and inflammation were assessed using three human acute myeloid cell lines (U937, HL‑60 and KG‑1a) in vitro. Additionally, the levels of several cytokines [interleukin (IL)‑2, IL‑10, IL‑17A and tumor necrosis factor (TNF)α] in AML cells and Sprague Dawley rats were evaluated to investigate the effects of PM2.5 on cytokine expression in AML. The results revealed that PM2.5 was capable of enhancing inflammatory responses in AML cells, and increasing IL‑2, IL‑10, IL‑17A and TNFα mRNA expression in AML cells to different degrees. Furthermore, PM2.5 increased IL‑2 and IL‑10 contents in rats following 12 weeks of exposure. These results suggested that PM2.5 may serve a role in promoting the occurrence and progression of leukemia by affecting cytokine expression, and that there may be various mechanisms active in different AML subtypes.

23 October 2020 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
XDXiaomin Dong
Xiaomin Dong
DZDanyang Zhang
Danyang Zhang
JZJuan Zhang
Juan Zhang
XCXiaolei Chen
Xiaolei Chen
YZYue Zhang
Yue Zhang
HZHebing Zhou
Hebing Zhou
Acute myeloid leukemia with normal karyotype (NK‑AML) is a group of diseases with high heterogeneity and immunological processes are significantly associated with its initiation and development. The implication of the immunogenomic landscape in the prognosis of patients with NK‑AML has remained largely elusive. In the present study, the expression profiles of immune‑related genes (IRGs) were examined and their association with overall survival (OS) was determined in 60 patients with NK‑AML from The Cancer Genome Atlas dataset and 104 patients from the Gene Expression Omnibus (GEO) dataset no. GSE71014. Univariate Cox regression analysis was used to identify 42 and 203 IRGs in the two respective cohorts, which were significantly associated with OS in NK‑AML. A risk model was constructed based on the regression coefficient and expression values of nine survival‑associated IRGs shared between the two datasets [zinc finger CCCH‑type containing, antiviral 1 like; transferrin receptor; suppressor of cytokine signaling 1; ELAV like RNA binding protein 1; roundabout guidance receptor 3; unc‑93 homolog B1, Toll‑like receptor signaling regulator; protein tyrosine phosphatase non‑receptor type 6; interleukin 2 receptor subunit alpha (IL2RA) and IL3RA]. Using this risk model, patients with NK‑AML may be divided into high‑ and low‑risk groups in prognostic predictions. The area under the receiver operating characteristic curve for predicting OS was 0.793. The prognostic role of this risk model was successfully verified in another independent cohort (GEO dataset no. GSE71014). The prognostic risk score was positively associated with age and fms related receptor tyrosine kinase 3 mutation and correlated with infiltration by T regulatory cells. In conclusion, the results of the present study provided an IRG score model for prognostic stratification of adult patients with NK‑AML, as well as further insight into the implication of IRGs in NK‑AML that may lead to the development of novel immunotherapy approaches for this disease.

26 November 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YTYing Tian
Ying Tian
YZYue Zhang
Yue Zhang
WZWan-Qiu Zhu
Wan-Qiu Zhu
XCXiao-Lei Chen
Xiao-Lei Chen
HZHebing Zhou
Hebing Zhou
Wenming ChenWenming Chen
Wenming Chen
The survival of individuals with tumors may be predicted by the peripheral blood lymphocyte-to-monocyte ratio (LMR) upon diagnosis in recent studies. For patients with multiple myeloma (MM) in the era of novel agents, the prognostic significance of LMR remains unclear. In this study, the prognostic impact of LMR is evaluated by 285 patients with MM who are treated with proteasome inhibitor and/or immunomodulatory drug. LMR is a proven predictor of survival using the receiver operating characteristic curve, with 4.2 as the cutoff point. Patients with LMR ≤ 4.2 at diagnosis had poorer overall survival (OS) and progression-free survival (PFS) than those with LMR > 4.2. In addition, multivariate analysis showed that LMR less than 4.2 is an independent predictor for the OS (hazard ratio [HR]: 1.703; 95% confidence interval [CI]: 1.020–2.842;P= 0.042) and PFS (HR: 1.831; 95% CI: 1.098–3.053;P= 0.021). According to the test, the LMR at diagnosis, which functions as a simple index reflecting host systemic immunity, can predict clinical outcomes in patients with MM who are treated with new agents.